Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  ALK-Abello A/S    ALK B   DK0060027142

Delayed Quote. Delayed  - 09/29 10:09:55 am
935 DKK   -0.53%
08/31 ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares..
08/24 ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares..
08/16 ALK ABELLO A/S : Six-month interim report (Q2) 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ALK-Abello A/S : Grant of share options and conditional shares to members of the Board of Management and key employees

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 10:19am CEST

Copenhagen, 2012-05-11 08:55 CEST (GLOBE NEWSWIRE) --

Share option programme
According to the guidelines for incentive pay adopted at the Company's annual general meeting on 27 March 2012, the Board of Directors has passed a resolution to grant a total of 101,000 share options, comprising 40,250 options to the members of the Board of Management and 60,750 options to a group of key employees.

The options can be exercised during the period from 1 May 2015 to 1 May 2019 during the four-week trading windows following the release of annual and interim reports. If the option holders have not exercised their options within the period specified, the options will lapse without any compensation to the holders.

The exercise price of the options has been set at DKK 399 each, corresponding to an average of the closing prices of the company's shares on the NASDAQ OMX Copen­hagen A/S during the period 2 - 9 May 2012 (both days included). To this should be added annual interest at the rate of 2.5%, which will be added the first time on 1 May 2013. The exercise price of the options will be adjusted on payment of dividend, to the effect that DKK 1 of dividend per share results in a reduction of the exercise price by DKK 1.

The market value of the adopted option plan of 101,000 options is approximately DKK 6 million applying the Black & Scholes model for valuation of options. The determination of the value is based on an assumed exercise price of DKK 440, an annual dividend distribution of DKK 5 per share, a volatility rate of 22% p.a. and a risk-free interest rate of 1.49% p.a.

Conditional share programme
The Board of Directors has passed a resolution to grant conditional shares in accordance with the guidelines for incentive pay adopted at the Company's annual general meeting. The scheme comprises a total of 15,300 conditional shares, including 6,100 shares to the members of the Board of Management and 9,200 shares to a group of key employees. The market value of the conditional shares is approximately DKK 6 million, calculated on the basis of an average of the closing prices of the company's shares on the NASDAQ OMX Copenhagen A/S during the period 2 - 9 May 2012 (both days included).

Conditional shares will be available in May 2015, three years following the date of grant, provided that ALK achieves the financial targets for vesting and that the employment relationship with the ALK Group has not been terminated by the Company on objective grounds or terminated during the three-year period from the date of grant in 2012.

Under the international financial reporting standards (IFRS), the incentive plans will be recognised in the income statement in the respective functional areas over the vesting period.

The grant of share options and conditional shares does not change the company's financial forecast.

No share options or conditional shares have been granted to members of the Board of Directors.



ALK-Abelló A/S

Steen Riisgaard
Chairman

For further information please contact:
Steen Riisgaard, Chairman of the Board of Directors, tel +45 4446 0000



distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALK-ABELLO A/S
08/31 ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
08/24 ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
08/16 ALK ABELLO A/S : Six-month interim report (Q2) 2016
08/11ALK-ABELLO A/S : half-yearly earnings release
08/08 ALK ABELLO A/S : Release date of six-month interim report (Q2) 2016 for ALK
07/26 ALK ABELLO A/S : All rights to ALK's SLIT-tablets in North America to revert to ..
06/12 Global data highlights worldwide challenge of house dust mite allergy
05/25 ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
05/20 ALK ABELLO A/S : Report on transactions with ALK-Abelló A/S B-shares and associa..
05/04 ALK ABELLO A/S : Three-month interim report (Q1) 2016
More news
Sector news : Pharmaceuticals - NEC
10:26aDJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ( DKK)
Sales 2016 2 964 M
EBIT 2016 460 M
Net income 2016 258 M
Finance 2016 129 M
Yield 2016 0,75%
P/E ratio 2016 36,70
P/E ratio 2017 28,34
EV / Sales 2016 2,88x
EV / Sales 2017 2,75x
Capitalization 8 655 M
More Financials
Chart ALK-ABELLO A/S
Duration : Period :
ALK-Abello A/S Technical Analysis Chart | ALK B | DK0060027142 | 4-Traders
Full-screen chart
Technical analysis trends ALK-ABELLO A/S
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 5
Average target price 967  DKK
Spread / Average Target 2,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Steen Riisgaard Chairman & Chief Executive Officer
Flemming Pedersen CFO, EVP-Finance, IT, IR & Business Development
Henrik Hugo Jacobi Executive Vice President-Research & Development
Anders Gersel Pedersen Independent Director
Jacob Kastrup Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALK-ABELLO A/S7.76%1 304
JOHNSON & JOHNSON16.23%326 636
ROCHE HOLDING LTD.-12.41%217 190
NOVARTIS AG-10.14%212 589
PFIZER INC.5.30%206 172
MERCK & CO., INC.19.84%175 038
More Results